Immunohistochemistry Market

Growing Digital Pathology Adoption Driving Market Growth

Market CAGR for Immunohistochemistry is being driven by the rising adoption of digital pathology. A laboratory technique called immunohistochemistry (IHC) uses antibodies to detect particular antigens in a tissue sample. Typically, the antibodies attach themselves to a fluorescent dye or an enzyme, allowing scientists to view the antigen under a microscope. IHC is frequently used to identify the various forms of chronic illnesses, including cancer. In contrast to traditional enzyme staining methods, which are limited in their ability to recognize certain proteins, enzymes, and tissue structures, immunohistochemistry (IHC) uses particular antigen-antibody reactions.

Additionally, the continued trend of automation of diagnostic laboratory operations across major healthcare markets has led to an increase in the use of digital pathology systems by healthcare practitioners worldwide. In order to eliminate the need for physical slides and to facilitate the efficient collaboration of pathologists and researchers, traditional IHC staining is combined with digital imaging and analysis tools in digital immunohistochemistry (IHC). This makes it possible to transform stained tissue slides into electronically stored, retrievable, and analyzed images.

Digital pathology application in IHC has several benefits: it does away with the need for handling and storing physical slides; it makes it easier for pathologists to collaborate remotely for case sharing and second opinions; it makes objective and standardized quantitative stain analysis possible; and it makes it possible to archive and integrate digital images with other data for thorough analysis and research.

Rising Importance of Companion Diagnostics

Assays and tests, referred to as companion diagnostics, are designed to support medical professionals in treating patients by helping them determine which course of action is best for them, depending on their optimal response to therapy. Through the swift and economical production of safer medications with improved therapeutic efficacy, the co-creation of companion diagnostics and therapeutic products holds the potential to drastically change the drug development process and commercialize drug candidates. Companion diagnostics has a promising future due to the rising need for safer medications and expensive specialized therapies.

The expanding significance of companion diagnostics is also creating potential prospects for the IHC market as well as the diagnostics segment.

For instance, For in vitro diagnostic medical devices, the European Parliament and Council of the European Union have released Regulation (EU) 2017/746. The current In Vitro Diagnostic Devices Directive (IVDD) 98/79/EC will be replaced by this resolution, and businesses will have five years to adapt to the more complicated and demanding new rules. Thus, result in driving the Immunohistochemistry market revenue.

The Global Immunohistochemistry Market Industry is poised for substantial growth, with projections indicating a market size of 8.81 USD Billion by 2035. This growth is underpinned by a compound annual growth rate (CAGR) of 8.0% from 2025 to 2035. Factors contributing to this expansion include the rising prevalence of chronic diseases, advancements in diagnostic technologies, and an increasing focus on personalized medicine. The market's trajectory suggests a robust demand for immunohistochemistry products and services, driven by the ongoing need for accurate and efficient diagnostic solutions. As the industry evolves, it is likely to witness innovations that further enhance its capabilities and applications.

Technological innovations in immunohistochemistry are transforming the landscape of diagnostics. The Global Immunohistochemistry Market Industry benefits from advancements such as automated staining systems and digital pathology. These technologies enhance accuracy and efficiency in diagnostic processes, allowing for quicker turnaround times and improved patient outcomes. For instance, the integration of artificial intelligence in image analysis is becoming increasingly prevalent, facilitating more precise interpretations of histological samples. As these technologies evolve, they are likely to attract investment and research, contributing to the market's expansion. The anticipated growth in the market, projected at a CAGR of 8.0% from 2025 to 2035, underscores the impact of these advancements.

The increasing incidence of cancer globally drives the demand for advanced diagnostic tools, including immunohistochemistry. As per estimates, the Global Immunohistochemistry Market Industry is projected to reach 3.78 USD Billion in 2024, reflecting a growing need for precise cancer diagnostics. Immunohistochemistry plays a crucial role in identifying specific biomarkers, which aids in personalized treatment plans. The rise in cancer cases necessitates the development of innovative diagnostic techniques, thereby propelling market growth. Furthermore, the World Health Organization indicates that cancer cases are expected to rise by 70 percent over the next two decades, further emphasizing the importance of immunohistochemistry in oncology.

The surge in research activities related to immunohistochemistry is a significant driver for the Global Immunohistochemistry Market Industry. Academic institutions and pharmaceutical companies are increasingly utilizing immunohistochemical techniques to explore disease mechanisms and develop new therapies. This trend is evident in the growing number of publications and clinical trials focusing on immunohistochemistry applications. As research funding increases, particularly in oncology and immunology, the demand for immunohistochemistry reagents and kits is expected to rise. This growing emphasis on research is likely to contribute to the market's projected growth, with estimates indicating a market size of 8.81 USD Billion by 2035.

The expansion of diagnostic laboratories globally is a key factor influencing the Global Immunohistochemistry Market Industry. As healthcare infrastructure improves, particularly in emerging economies, the establishment of new diagnostic facilities is on the rise. These laboratories are increasingly adopting immunohistochemistry techniques to enhance their diagnostic capabilities. The growing awareness of the importance of early disease detection is driving this trend. Furthermore, collaborations between diagnostic companies and healthcare providers are facilitating the integration of advanced immunohistochemistry technologies in routine diagnostics. This expansion is expected to contribute to the market's growth, aligning with the projected increase in market size to 3.78 USD Billion in 2024.

The shift towards personalized medicine is reshaping the Global Immunohistochemistry Market Industry. Immunohistochemistry is pivotal in identifying specific biomarkers that guide tailored treatment strategies for patients. As healthcare systems increasingly adopt personalized approaches, the demand for immunohistochemical assays is likely to rise. This trend is supported by the increasing recognition of the importance of individualized therapies in improving patient outcomes. Moreover, regulatory bodies are encouraging the development of targeted therapies, further driving the need for precise diagnostic tools. The market's growth trajectory, with a projected CAGR of 8.0% from 2025 to 2035, reflects the expanding role of immunohistochemistry in personalized medicine.

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Immunohistochemistry market area will dominate this market because of elements like the high rate of cancer and other chronic diseases in the area, the existence of important figures, and the well-established healthcare infrastructure.

Further, the major countries studied in the market report are China, Japan, India, Australia, South Korea, Germany, France, the UK, and Italy.

Europe Immunohistochemistry Market

Europe Immunohistochemistry market has the second-largest portion of the market. This is linked to an increase in the region's cases of chronic diseases management. Further, the German Immunohistochemistry market held the largest market share, and the UK Immunohistochemistry market was the European market with the quickest rate of growth.

Asia-Pacific Immunohistochemistry Market

The Asia-Pacific Immunohistochemistry Market is anticipated to expand between 2025 and 2034 at the quickest CAGR. The high prevalence of chronic illnesses and the population's quick aging are two further elements propelling the Asia-Pacific Immunohistochemistry Industry's expansion. Moreover, China’s Immunohistochemistry market held the largest market share, and the Indian Immunohistochemistry market was the Asia-Pacific region's fastest-growing market.

Figure 2:  Immunohistochemistry Market Share By Region 2023 (USD Billion)

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Leading market players are putting a lot of money into R&D to expand their product lines, which will help the immunohistochemistry market to keep growing. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, the Immunohistochemistry industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the Immunohistochemistry industry to help customers and expand the market segment. In recent years, the Immunohistochemistry industry has provided some of the biggest benefits to medicine. Major players in the Immunohistochemistry market, including Bio-Rad Laboratories Inc. (US), Eagle Biosciences Inc. (US), Danaher Corporation (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), F. Hoffmann-LA-Roche AG (Switzerland), and Biocare Medical LLC. (US), and others are engaging in research and development activities in an effort to boost market demand.

Hoffmann-La Roche AG (Roche)

Hoffmann-La Roche AG, or Roche for short, is a multinational healthcare corporation based in Switzerland that operates in two divisions: diagnostics and pharmaceuticals. Shares of Roche Holding AG, the company's parent, are traded on the SIX Swiss Exchange. Basel is home to the corporate headquarters. By revenue, Roche is the fifth-largest pharmaceutical firm in the world and the world's top supplier of cancer medicines. In October 2023, The US FDA approved F.

Hoffman-La Roche AG (Switzerland) to employ PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody as a companion diagnostic test to find patients with low HER2 expression who have metastatic breast cancer.

Danaher Corporation

Danaher Corporation is an internationally diversified American corporation. The company is based in Washington, D.C., and creates, produces, and sells goods and services for the commercial, industrial, and medical sectors. In the past, it has made an effort to keep a very low public image and has mostly expanded through acquisitions. Kaizen is a lean manufacturing strategy from Japan that emphasizes continual improvement and waste elimination. Danaher was one of the first corporations in North America to adopt this methodology.

In August 2023, Danaher declared that it had finalized an agreement to buy Abcam for about $5.7 billion, payable in cash at $24 per share.